SG Power Limited has officially transformed its business strategy by changing its principal line of business from power generation to the healthcare and pharmaceutical industry. The transition marks a significant milestone for the company as it seeks to capitalize on emerging opportunities in Pakistan’s growing healthcare market.

The company announced the development through a notice submitted to the Pakistan Stock Exchange (PSX), confirming that all required corporate and regulatory approvals have been successfully completed. The decision follows the approval of shareholders through a special resolution passed during the Extraordinary General Meeting (EGM) held on May 13, 2026.

Following the shareholders’ approval, the necessary amendments were registered with the Securities and Exchange Commission of Pakistan (SECP), officially allowing SG Power to pursue its new business direction.

Under the revised Memorandum of Association, the company is now authorized to engage in a wide range of healthcare-related activities. These include the import, export, manufacturing, distribution, marketing, installation, maintenance, and sale of medical equipment, medical devices, hospital supplies, and other healthcare products.

In addition to medical equipment, SG Power will also be permitted to manufacture, trade, and distribute pharmaceutical, medicinal, and allied healthcare products. The company clarified that all such operations will remain subject to the applicable regulatory approvals and compliance requirements.

As part of its corporate transformation, SG Power is also working to change its company name to better represent its new focus on the healthcare and pharmaceutical industries. The company stated that it will inform the Pakistan Stock Exchange and its shareholders once the name change receives the necessary approvals and becomes effective.

The strategic shift reflects SG Power’s intention to diversify its operations and position itself in sectors with long-term growth potential. Pakistan’s healthcare and pharmaceutical industries continue to expand due to rising demand for quality medical services, healthcare products, and pharmaceutical manufacturing, making the move a notable development for investors and the broader market.

Company officials described the transition as an important step in SG Power’s long-term growth strategy. By securing the necessary regulatory framework, the company believes it is now well-positioned to explore new business opportunities while contributing to the development of Pakistan’s healthcare ecosystem.

The move also highlights a broader trend of corporate diversification, where listed companies are exploring new sectors to strengthen future growth and create additional value for shareholders. Investors will now closely watch SG Power’s execution strategy as it begins its journey in the healthcare and pharmaceutical industry.